cheaptrix/billsum-US_congress_and_house huggingface dataset:
Prompt Approval of Safe Generic Drugs Act

To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes. 1. Short title This Act may be cited as the Prompt Approval of Safe Generic Drugs Act 2. Heading Section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 (z) Prompt approval of drugs when safety information is added to labeling (1) General rule A drug for which an application has been submitted or approved under subsection (b)(2) or (j) shall not be considered ineligible for approval under this section or misbranded under section 502 on the basis that the labeling of the drug omits safety information, including contraindications, warnings, precautions, dosing, administration, or other information pertaining to safety, when the omitted safety information is protected by exclusivity under clause (iii) or (iv) of subsection (c)(3)(E), clause (iii) or (iv) of subsection (j)(5)(F), or section 527(a), or by an extension of such exclusivity under section 505A or 505E. (2) Labeling Notwithstanding clauses (iii) and (iv) of subsection (c)(3)(E), clauses (iii) and (iv) of subsection (j)(5)(F), or section 527, the Secretary shall require that the labeling of a drug approved pursuant to an application submitted under subsection (b)(2) or (j) that omits safety information described in paragraph (1) include a statement of any appropriate safety information that the Secretary considers necessary to assure safe use. (3) Availability and scope of exclusivity This subsection does not affect— (A) the availability or scope of exclusivity or an extension of exclusivity described in subparagraph (A) or (B) of section 505A(o)(3); (B) the question of the eligibility for approval under this section of any application described in subsection (b)(2) or (j) that omits any other aspect of labeling protected by exclusivity under— (i) clause (iii) or (iv) of subsection (c)(3)(E); (ii) clause (iii) or (iv) of subsection (j)(5)(F); or (iii) section 527(a); or (C) except as expressly provided in paragraphs (1) and (2), the operation of this section or section 527. .

Summary: Prompt Approval of Safe Generic Drugs Act This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a drug even if the drug's labeling lacks certain safety information. Specifically, an abbreviated application for approval of a generic drug shall not be ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's exclusivity protections. Similarly, a drug that is approved under this bill shall not be considered mislabeled for lacking such safety information. Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug. For any drug approved under this bill, the FDA shall require the drug's labeling to include any safety information that is necessary to assure safe use.
Don’t Tax Higher Education Act

To amend the Internal Revenue Code of 1986 to repeal the excise tax on investment income of private colleges and universities. 1. Short title This Act may be cited as the Don’t Tax Higher Education Act 2. Repeal of excise tax on investment income of private colleges and universities (a) In general Chapter 42 (b) Effective date The amendments made by this section shall apply to taxable years beginning after the date of the enactment of this Act.

Summary: Don't Tax Higher Education Act This bill repeals the excise tax on the net investment income of certain private colleges and universities.
Protecting Miranda Rights for Kids Act

To protect minors from premature waiver of their constitutional rights during a custodial interrogation, and for other purposes. 1. Short title This Act may be cited as the Protecting Miranda Rights for Kids Act 2. Waiver of Miranda rights by a minor (a) In general Chapter 223 section 3051 3501A. Custodial interrogation of a minor (a) Notification Any law enforcement officer who has arrested a minor for a violation of law shall notify the minor's parent, guardian, or legal custodian that the minor has been arrested and shall provide the location of where the minor is being detained. (b) Waiver A minor who is subject to a custodial interrogation may only waive the privilege against self-incrimination or the right to assistance of legal counsel if the minor consults with legal counsel in person before such waiver. (c) Exception Subsection (a) shall not apply if— (1) custodial interrogation of a minor is necessary to gather information to protect life from an imminent threat; and (2) the questions that were asked during the custodial interrogation were reasonably necessary to obtain such information. (d) Assigned counsel (1) In general A minor who is subject to a custodial interrogation shall have the right to have the legal counsel assigned to the minor’s case physically present during such interrogation. (2) Violation In the case of custodial interrogation of a minor, it shall be a violation of this subsection for the minor to be represented by any substitute counsel temporarily assigned to represent the minor. (e) Inadmissible In any criminal prosecution brought by the United States, any statement given by a minor during a custodial interrogation that does not comply with this section, and any evidence derived from that statement, shall be inadmissible. (f) Minor defined In this section, the term minor . (b) Clerical amendment The table of sections for chapter 223 section 3501 3501A. Custodial interrogation of a minor. .

Summary: Protecting Miranda Rights for Kids Act This bill establishes procedural requirements related to the custodial interrogation of a minor. Among the requirements, the custodial interrogation of a minor must comply with the following: an arresting officer must notify the minor's parent, guardian, or legal custodian of the arrest and provide the location where the minor is being detained; and a minor who is subject to a custodial interrogation must consult with legal counsel in person before waiving the privilege against self-incrimination or the right to counsel. If a custodial interrogation does not comply with the requirements, then a statement by a minor during the custodial interrogation and any evidence derived from that statement are inadmissible.
Making Essentials Available and Lawful (MEAL) Act of 2021

To amend the Personal Responsibility and Work Opportunity Reconciliation Act of 1996 to repeal a certain disqualification to receive benefits under title IV of the Social Security Act and benefits under the Food and Nutrition Act of 2008; and to amend the Food and Nutrition Act of 2008 to provide that incarcerated individuals who are scheduled to be released from an institution within 30 days shall be considered to be a household for purposes of such Act. 1. Short title This Act may be cited as the Making Essentials Available and Lawful (MEAL) Act of 2021 2. Tanf assistance and SNAP benefits (a) Repeal of ban on assistance Section 115 of the Personal Responsibility and Work Opportunity Reconciliation Act of 1996 ( 21 U.S.C. 862a (b) Effect on State elections To opt out or limit period of prohibition (1) Definitions In this subsection— (A) the term State 21 U.S.C. 862a(e) (B) the term TANF assistance or SNAP benefits (2) Effect on State policies Any law enacted by a State under the authority under subparagraph (A) or (B) of subsection (d)(1) of section 115 of the Personal Responsibility and Work Opportunity Reconciliation Act of 1996 ( 21 U.S.C. 862a 3. Modification of definition of household for the purpose of determining SNAP benefits Section 3(m)(5) of the Food and Nutrition Act of 2008 ( 7 U.S.C. 2012(m)(5) (H) Incarcerated individuals who are scheduled to be released from an institution within 30 days. .

Summary: Making Essentials Available and Lawful (MEAL) Act of 2021 This bill repeals a lifetime ban that prohibits individuals convicted of certain offenses related to the possession, use, or distribution of a controlled substance from receiving Supplemental Nutrition Assistance Program (SNAP) benefits or assistance under programs funded by Temporary Assistance for Needy Families (TANF) block grants. Any state law that imposes conditions on eligibility for SNAP benefits or TANF assistance based on an individual's conviction of such an offense shall have no force or effect. In addition, individuals who are incarcerated and scheduled to be released within 30 days shall qualify as individual households for purposes of SNAP eligibility. Under current law, unless specifically excepted, individuals residing in institutions do not constitute a household.
Require USCP to Utilize Body-Worn Cameras Act

To require uniformed officers of the United States Capitol Police to utilize body-worn cameras while on duty. 1. Short title This Act may be cited as the Require USCP to Utilize Body-Worn Cameras Act 2. Requiring uniformed United States Capitol Police officers to utilize body-worn cameras while on duty (a) Requirement Each uniformed officer of the United States Capitol Police whose job duties include interacting with the general public shall utilize a body-worn camera and ensure that the body-worn camera is activated while on duty. (b) Exception for officers on personal protection detail Subsection (a) does not apply to an officer during any time in which the officer is serving on a personal protection detail. (c) Regulations The Capitol Police Board shall promulgate such regulations as may be necessary to carry out this Act.

Summary: Require USCP to Utilize Body-Worn Cameras Act This bill requires each uniformed officer of the U.S. Capitol Police whose job duties include interacting with the general public to use a body-worn camera and ensure it is activated while on duty. This requirement does not apply to an officer serving on a personal protection detail.
To extend the authorization of each of the National Coal Heritage Area and the Wheeling National Heritage Area in the State of West Virginia, and for other purposes.

To extend the authorization of each of the National Coal Heritage Area and the Wheeling National Heritage Area in the State of West Virginia, and for other purposes. 1. Extension of National Heritage Area authorizations (a) National Coal Heritage Area Section 107 of Division II of the Omnibus Parks and Public Lands Management Act of 1996 ( Public Law 104–333 2021 2036 (b) Wheeling National Heritage Area Section 157(i) of the Department of the Interior and Related Agencies Appropriations Act, 2001 ( Public Law 106–291 2021 2036 (c) Extension of deadline To complete certain management plans Section 6001(c)(1) of the John D. Dingell, Jr. Conservation, Management, and Recreation Act ( 54 U.S.C. 320101 Public Law 116–9 3 4

Summary: This bill extends through FY2036 the authority of the Department of the Interior to make any grants or provide any assistance for the National Coal Heritage Area and the Wheeling National Heritage Area in West Virginia. The bill extends by one year the deadline for completion of proposed management plans for the Appalachian Forest National Heritage Area in West Virginia and Maryland, the Maritime Washington National Heritage Area in Washington. the Mountains to Sound Greenway National Heritage Area in Washington, the Sacramento-San Joaquin Delta National Heritage Area in California, the Santa Cruz Valley National Heritage Area in Arizona, and the Susquehanna National Heritage Area in Pennsylvania.
Nuclear Weapons Abolition and Economic and Energy Conversion Act of 2021

To provide for nuclear weapons abolition and economic conversion in accordance with District of Columbia Initiative Measure Number 37 of 1992, while ensuring environmental restoration and clean-energy conversion. 1. Short title This Act may be cited as the Nuclear Weapons Abolition and Economic and Energy Conversion Act of 2021 2. Requirement for nuclear weapons abolition and economic and energy conversion (a) In general The United States Government shall— (1) provide leadership by signing and ratifying the United Nations Treaty on the Prohibition of Nuclear Weapons or any other international agreement that provides for— (A) the dismantlement and elimination of all nuclear weapons in every country; and (B) strict and effective international control of such dismantlement and elimination; (2) redirect resources that are being used for nuclear weapons programs to use— (A) in converting all nuclear weapons industry processes, plants, and programs, and in retraining employees, to shift to a constructive, ecologically beneficial peace economy, which includes strict control of all fissile material and radioactive waste; and (B) in addressing human and infrastructure needs, including development and deployment of sustainable carbon-free and nuclear-free energy sources, health care, housing, education, agriculture, and environmental restoration, including long-term radioactive waste monitoring; and (3) actively promote policies to induce all other countries to join in the commitments described in this subsection to create a more peaceful and secure world. (b) Effective date Paragraph (2) of subsection (a) shall take effect on the date on which the President certifies to Congress that all countries possessing nuclear weapons have begun the elimination of such weapons under established legal requirements comparable to those described in paragraph (1) of such subsection.

Summary: Nuclear Weapons Abolition and Economic and Energy Conversion Act of 2021 This bill directs the U.S. government to sign and ratify the United Nations Treaty on the Prohibition of Nuclear Weapons or a similar international agreement that calls for the elimination of all nuclear weapons in every country. The government shall (1) redirect resources currently used in nuclear weapons programs toward building an ecologically beneficial peace economy and addressing human and infrastructure needs, and (2) actively promote policies to induce all other countries to take similar actions.
BLOCKING Act of 2021

To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes. 1. Short title This Act may be cited as the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021 BLOCKING Act of 2021 2. Change conditions of first generic exclusivity to spur access and competition Clause (iv) of section 505(j)(5)(B) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(5)(B) (1) in subclause (I), after 180 days after the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant or by an applicant whose application is approved pursuant to subclause (III) (2) by adding at the end the following new subclause: (III) Applicant approval An application containing a certification described in paragraph (2)(A)(vii)(IV) that is for a drug for which a first applicant has submitted an application containing such a certification can be approved notwithstanding the eligibility of a first applicant for the 180-day exclusivity period described in subclause (II)(aa) if each of the following conditions is met: (aa) The approval of such an application could be made effective, but for the eligibility of a first applicant for 180-day exclusivity under this clause. (bb) At least 30 months have passed since the date of submission of an application for the drug by at least one first applicant. (cc) Approval of an application for the drug submitted by at least one first applicant is not precluded under clause (iii) (dd) No application for the drug submitted by any first applicant is approved at the time the conditions under items (aa), (bb), and (cc) are all met, regardless of whether such an application is subsequently approved. .

Summary: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021 or the BLOCKING Act of 2021 This bill modifies provisions related to market exclusivity for a generic drug. Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug. The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.
Utility Resilience and Reliability Act

To amend the Federal Power Act to require the Electric Reliability Organization to propose a reliability standard that addresses the resilience of the bulk-power system, and for other purposes. 1. Short title This Act may be cited as the Utility Resilience and Reliability Act 2. Proposed reliability standard Section 215(d) of the Federal Power Act ( 16 U.S.C. 824o(d) (7) Resilience of bulk-Power system (A) In general Not later than 1 year after the date of enactment of this paragraph, the Electric Reliability Organization shall file with the Commission a proposed reliability standard that addresses the resilience of the bulk-power system. (B) Regional differences The proposed reliability standard filed under subsection (A) shall take into account regional differences. (C) Resilience defined In this paragraph, the term resilience (i) prepare for and adapt to changing conditions; and (ii) withstand and rapidly recover from disruptions, including disruptions caused by extreme weather conditions. . 3. Electric grid resilience education program (a) In general Not later than 1 year after the date of enactment of this section, the Secretary of Energy shall establish a program to provide information and recommendations to States and electric utilities on how to improve the resilience of electric grids. (b) Electric utility defined The term electric utility 16 U.S.C. 796 4. Report on planned electric power outages due to extreme weather conditions Not later than 1 year after the date of enactment of this section, the Secretary of Energy shall submit to Congress a report, and publish such report on the website of the Department of Energy, that provides recommendations on how to minimize the need for, effects of, and duration of planned electric power outages that are due to extreme weather conditions, including such conditions under which the National Weather Service issues a red flag warning.

Summary: Utility Resilience and Reliability Act This bill addresses the reliability of electric energy provided by the bulk-power system, which includes facilities and control systems necessary for operating an interconnected electric energy transmission network. Specifically, the Electric Reliability Organization must file with the Federal Energy Regulatory Commission a proposed reliability standard that addresses the resilience of the bulk-power system. For example, the standard must address the system's ability to withstand and rapidly recover from disruptions, such as extreme weather conditions. The standard must take into account regional differences. In addition, the Department of Energy (DOE) must establish a program to provide information and recommendations to states and electric utilities on how to improve the resilience of electric grids. DOE must also post on its website a report that provides recommendations on how to minimize the need for, effects of, and duration of planned electric power outages that are due to extreme weather conditions.
Star Rating for Biosimilars Act

To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to add a new set of measures to the 5-star rating system under the Medicare Advantage program in order to encourage increased access to biosimilar biological products. 1. Short title This Act may be cited as the Star Rating for Biosimilars Act 2. Addition of new measures based on access to biosimilar biological products to the 5-star rating system under medicare advantage (a) In general Section 1853(o)(4) of the Social Security Act ( 42 U.S.C. 1395w–23(o)(4) (E) Addition of new measures based on access to biosimilar biological products (i) In general For 2022 and subsequent years, the Secretary shall add a new set of measures to the 5-star rating system based on access to biosimilar biological products covered under part B and, in the case of MA–PD plans, such products that are covered part D drugs. Such measures shall assess the impact a plan’s benefit structure may have on enrollees’ utilization of or ability to access biosimilar biological products, including in comparison to the reference biological product, and shall include measures, as applicable, with respect to the following: (I) Coverage Assessing whether a biosimilar biological product is on the plan formulary in lieu of or in addition to the reference biological product. (II) Preferencing Assessing tier placement or cost sharing for a biosimilar biological product relative to the reference biological product. (III) Utilization management tools Assessing whether and how utilization management tools are used with respect to a biosimilar biological product relative to the reference biological product. (IV) Utilization Assessing the percentage of enrollees prescribed the biosimilar biological product when the reference biological product is also available. (ii) Definitions In this subparagraph, the terms biosimilar biological product reference biological product (iii) Protecting patient interests In developing such measures, the Secretary shall ensure that each measure developed to address coverage, pref­er­enc­ing, or utilization management is constructed such that patients retain equal access to appropriate therapeutic options without undue administrative burden. . (b) Clarification regarding application to prescription drug plans To the extent the Secretary of Health and Human Services applies the 5-star rating system under section 1853(o)(4) of the Social Security Act ( 42 U.S.C. 1395w–23(o)(4)

Summary: Star Rating for Biosimilars Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management. The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.